2023-03-17 08:31:18 ET
- Ra Medical Systems ( NYSE: RMED ) said its unit Catheter Precision will get a patent in Japan linked to the company's VIVO technology.
- The patent is titled, 'Methods of Cardiac Mapping and Model Merging.'
- VIVO is a non-invasive 3D imaging system which helps physicians to identify the origin of ventricular arrhythmias pre-procedure.
- Ventricular arrhythmias are abnormal heartbeats which start in the lower heart chambers known as ventricles. This cause the heart to beat too fast.
- "We are pleased that our technology in the field of cardiac electrophysiology continues to be recognized as unique and different," said Ra Medical's Executive Chairman David Jenkins.
- RMED +9.94% to $2.10 premarket March 17
For further details see:
Ra Medical stock rises ~10% on Japanese patent linked to imaging system